<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A4FD168-BA47-429C-A08E-6512EC723D43"><gtr:id>4A4FD168-BA47-429C-A08E-6512EC723D43</gtr:id><gtr:name>International Centre for Genetic Engineering and Biotechnology (ICGEB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1B116AEE-BBD8-4B73-93CF-DCB8A5573C94"><gtr:id>1B116AEE-BBD8-4B73-93CF-DCB8A5573C94</gtr:id><gtr:name>National University of Singapore</gtr:name><gtr:address><gtr:line1>National University of Singapore</gtr:line1><gtr:line2>10 Kent Ridge Crescent</gtr:line2><gtr:line4>Singapore</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Singapore</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Central Admin - Research Services</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A4FD168-BA47-429C-A08E-6512EC723D43"><gtr:id>4A4FD168-BA47-429C-A08E-6512EC723D43</gtr:id><gtr:name>International Centre for Genetic Engineering and Biotechnology (ICGEB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1B116AEE-BBD8-4B73-93CF-DCB8A5573C94"><gtr:id>1B116AEE-BBD8-4B73-93CF-DCB8A5573C94</gtr:id><gtr:name>National University of Singapore</gtr:name><gtr:address><gtr:line1>National University of Singapore</gtr:line1><gtr:line2>10 Kent Ridge Crescent</gtr:line2><gtr:line4>Singapore</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Singapore</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/72056FF9-D3CE-4186-BD73-491ABDB4EA85"><gtr:id>72056FF9-D3CE-4186-BD73-491ABDB4EA85</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Draper</gtr:surname><gtr:orcidId>0000-0002-9415-1357</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100086"><gtr:id>2F7C630C-6F1D-4255-839F-3B4FD2962025</gtr:id><gtr:title>Developmental Clinical Studies - Clinical evaluation of an AdCh63-MVA PvDBP_RII vaccine for blood-stage Plasmodium vivax</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100086</gtr:grantReference><gtr:abstractText>Malaria is one of the greatest causes of infectious mortality globally but no vaccine is available. The blood-stage of the parasite?s life-cycle is the one that causes all the symptoms of disease and very often death. Five different types of parasite cause malaria disease in humans. Most research in the last few decades has focussed on one of these parasites ? called Plasmodium falciparum. This parasite is responsible for most of the deaths every year due to malaria infection.

Many vaccines against blood-stage infection with Plasmodium falciparum have been tested in clinical trials but always with disappointing results. This is most likely because this parasite has many different ways to infect red blood cells. Consequently if a vaccine stops one invasion pathway, the parasite will simply switch to a different one and continue with the infection process.

A second malaria parasite, called Plasmodium vivax, is far more widespread worldwide. Although it doesn?t kill infected individuals, infection with this parasite causes a debilitating and severe illness that often relapses months or years later. This parasite, like Plasmodium falciparum, exerts a huge and unacceptable health burden on the wider developing world. However, this parasite may be more amenable to the effects of a blood-stage vaccine. It can only use a single invasion pathway to infect red blood cells, and a vaccine targeting this one pathway may stand a much greater chance of success. 

Here we propose to use a new vaccine delivery technology to target this invasion pathway of Plasmodium vivax. Vectored vaccines use a crippled but safe virus to produce the malaria protein inside the injection site of the vaccinee. This technology has recently been shown to be safe and capable of inducing strong immune responses in human clinical trials at Oxford University. In this application we therefore propose to test a new pair of vectored vaccines against the blood-stage of Plasmodium vivax malaria for the first time in humans. We will develop these new vaccines and test their safety and immune-stimulating capacity in a clinical trial in healthy adult volunteers. This study should provide a critical test of the possibility that such vectored vaccines could be useful in inducing immune responses that may protect people against infection with the Plasmodium vivax form of malaria.</gtr:abstractText><gtr:technicalSummary>The Need: Plasmodium vivax, one of the five Plasmodium species to cause human malaria, is the most widespread geographically and has been viewed, most certainly incorrectly, as a ?benign? parasite. In fact over 80 million cases of P. vivax malaria are reported annually, leading to severe morbidity for inhabitants of endemic areas as well as some mortality. 
Rationale: In recent years, viral vectored vaccines have been developed targeting the P. falciparum blood-stage malaria antigens MSP1 and AMA1. In Phase I/IIa clinical trials these vectors have induced strong serum antibody responses, unprecedented levels of cellular immunity and the first demonstration of efficacy with these antigens, albeit modest, in a human sporozoite challenge study. Unlike P. falciparum which utilises multiple redundant invasion pathways for human erythrocyte invasion, P. vivax requires an interaction with the Duffy blood group antigen, which is mediated by region II of the P. vivax Duffy-binding protein (PvDBP_RII). Given the essential nature of this invasion pathway, this candidate P. vivax antigen stands a far greater chance of success in comparison to the widely tested merozoite targets of P. falciparum. 
Solution &amp;amp; Development Plan: We have recently developed AdCh63 and MVA vectors expressing PvDBP_RII, and have shown in pre-clinical animal studies that, like for PfMSP1 and PfAMA1, these vectors induce strong antibody and cellular immunogenicity. This proposal aims to manufacture these two vectors to GMP and undertake a Phase Ia clinical trial to assess the safety, immunogenicity and in vitro efficacy of these new candidate vaccines for blood-stage P. vivax. If successful, these vaccines would be lead candidates for future efficacy testing.</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>895438</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>NIMR</gtr:description><gtr:id>5BA79ACB-643B-4D69-BB87-A28BACE555E9</gtr:id><gtr:impact>Publications.
PMID: 20713623
PMID: 22504652
PMID: 21781305
PMID: 21698193</gtr:impact><gtr:partnerContribution>Sharing of research reagents.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Centre for Genetic Engineering and Biotechnology (ICGEB)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>ICGEB</gtr:description><gtr:id>D81950A6-DDA9-4879-891E-872B800B75A4</gtr:id><gtr:impact>Secured grant funding.
Publication.
PMID: 21813775</gtr:impact><gtr:partnerContribution>Sharing of research materials. MRC DCS grant collaborator.</gtr:partnerContribution><gtr:piContribution>Sharing of research materials and grant collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National University of Singapore</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>University of Singapore, A*</gtr:description><gtr:id>5F5C664C-AE8F-4ADD-8B82-69F7C0FF3DEE</gtr:id><gtr:impact>Publication and grant applications in progress</gtr:impact><gtr:partnerContribution>Vaccine and mAb provision, assay design</gtr:partnerContribution><gtr:piContribution>Vaccine testing collaboration for P. vivax</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Okairos/GSK</gtr:description><gtr:id>E855EDDD-49CB-4818-BBEB-849409CF44E5</gtr:id><gtr:impact>Grants secured - EU FP7 MultiMalVax.
Publications.
PMID: 22363582
PMID: 21862998
PMID: 21098232
PMID: 20713623
PMID: 23089736
PMID: 21698193
PMID: 23293353</gtr:impact><gtr:partnerContribution>Access to expertise and reagents.
Vaccine manufacture.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Online Interview</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11BE54C8-238B-496C-BC5D-647B54CB4868</gtr:id><gtr:impact>Online interview/podcast for the European Vaccine Initiative website

Online public engagement.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit. Nottingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9216CCD-2D36-447C-9F1F-7704514D47A7</gtr:id><gtr:impact>50 pupils attended a careers talk, which sparked questions and discussion afterwards

School asked for lab / university visit for sixth form pupils and university application guidance</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Departmental Podcast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5FCEA6B5-6D10-4AD7-9CA6-96BAD36842E3</gtr:id><gtr:impact>Podcast about my reserach for Public access on the NDM website.

Public access on website.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ndm.ox.ac.uk/simon-draper-progress-in-malaria-vaccine-research</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lister Institute Research Prize 2013</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Lister Institute of Preventive Medicine</gtr:fundingOrg><gtr:id>CE53236B-2693-4057-BDD2-7991744D469E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>MultiViVax</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>40F04095-EB1F-421B-8B38-8BE28A3D3969</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1901424</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Research Fellowship</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>106917/Z/15/Z</gtr:fundingRef><gtr:id>2EAE3FF0-C1DD-4228-8454-EC423715F1B9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>University of Oxford MRC CiC</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E936C61A-EF79-4686-9C4B-49276DC05608</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EVI European Vaccine Workshop</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B794AE7F-40EC-4CAD-BC24-DC4A0E82FB1A</gtr:id><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26431986</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Gates Foundation - P. vivax: Filling the R&amp;amp;D Gap Workshop</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>3D628FD5-6091-494E-A2A1-50792E680732</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Viral vectored vaccine against blood-stage Plasmodium vivax - supported by MRC DPFS grant. Phase Ia clinical trial commenced in April 2013 and now completed.</gtr:description><gtr:id>C3B53338-1E8D-4195-98AB-7FEA911AB688</gtr:id><gtr:impact>Grant income. Publications in preparation.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>P. vivax vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT01816113?term=NCT01816113&amp;rank=1</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B84A703-35E9-46DD-B84D-3B2002D974D2"><gtr:id>0B84A703-35E9-46DD-B84D-3B2002D974D2</gtr:id><gtr:title>Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42a04bc2b2520d2067cacef47b23c82b"><gtr:id>42a04bc2b2520d2067cacef47b23c82b</gtr:id><gtr:otherNames>de Cassan SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/05BDB9D3-0D81-45FE-BE64-85490A3661DC"><gtr:id>05BDB9D3-0D81-45FE-BE64-85490A3661DC</gtr:id><gtr:title>Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e431dee7e091b64744115afa9fea7ab"><gtr:id>1e431dee7e091b64744115afa9fea7ab</gtr:id><gtr:otherNames>Payne RO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100086</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>